Crinetics Pharmaceuticals (CRNX) Non-Current Deffered Revenue (2017 - 2026)
Crinetics Pharmaceuticals' quarterly Non-Current Deffered Revenue came in at $3.3 million in Q1 2026, down 22.42% year-on-year from $4.3 million in Q1 2025, and down 12.18% quarter-over-quarter from $3.8 million in Q4 2025.
Crinetics Pharmaceuticals has reported Non-Current Deffered Revenue for 10 years, with the latest figure at $3.3 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 22.42% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 million (down 22.42% YoY), and the FY2025 full-year result was $3.8 million, down 19.01% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $3.3 million, down from $3.8 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $7.2 million in Q1 2022, with the low at $3.3 million in Q1 2026.
- Average Non-Current Deffered Revenue over 5 years is $5.1 million, with a median of $4.8 million recorded in 2023.
- Year-over-year, Non-Current Deffered Revenue surged 94928.57% in 2022 and slipped 26.36% in 2023.
- Tracing CRNX's Non-Current Deffered Revenue over 5 years: stood at $6.1 million in 2022, then retreated by 22.14% to $4.8 million in 2023, then fell by 0.97% to $4.7 million in 2024, then retreated by 19.01% to $3.8 million in 2025, then dropped by 12.18% to $3.3 million in 2026.
- The last three Non-Current Deffered Revenue figures came in at $3.3 million (Q1 2026), $3.8 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn | 3.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.35 Mn |
| Dec 31, 2025 | 3.81 Mn |
| Sep 30, 2025 | 4.11 Mn |
| Jun 30, 2025 | 3.99 Mn |
| Mar 31, 2025 | 4.31 Mn |
| Dec 31, 2024 | 4.70 Mn |
| Sep 30, 2024 | 5.20 Mn |
| Jun 30, 2024 | 4.32 Mn |
| Mar 31, 2024 | 4.74 Mn |
| Dec 31, 2023 | 4.75 Mn |
| Sep 30, 2023 | 5.14 Mn |
| Jun 30, 2023 | 5.07 Mn |
| Mar 31, 2023 | 5.62 Mn |
| Dec 31, 2022 | 6.10 Mn |
| Sep 30, 2022 | 6.65 Mn |
| Jun 30, 2022 | 6.89 Mn |
| Mar 31, 2022 | 7.16 Mn |
| Sep 30, 2021 | 7,000.00 |
| Jun 30, 2021 | 12,000.00 |
| Mar 31, 2021 | 18,000.00 |
| Dec 31, 2020 | 23,000.00 |
| Sep 30, 2020 | 28,000.00 |
| Jun 30, 2020 | 34,000.00 |
| Mar 31, 2020 | 39,000.00 |
| Dec 31, 2019 | 49,000.00 |
| Sep 30, 2019 | 60,000.00 |
| Jun 30, 2019 | 72,000.00 |
| Mar 31, 2019 | 150,000.00 |
| Dec 31, 2018 | 3.06 Mn |
| Sep 30, 2018 | 3.44 Mn |
| Jun 30, 2018 | 217,000.00 |
| Dec 31, 2017 | 20,000.00 |